Drugs in the CSD: Top 200 Pharmaceutical Products by Retail Sales 2023

1 **Keytruda** *Pembrolizumab* $25.011 Billion Oncology	2 **Eliquis** *Apixaban* NUPQEW $18.953 Billion Cardiology/Vascular Diseases	3 **Ozempic** *Semaglutide* $18.468 Billion Diabetes	4 **Humira** *Adalimumab* $14.494 Billion Immunology	5 **Biktarvy** *Bictegravir, Emtricitabine & Tenofovir Alafenamide* HAKJIM, BUKQOQ $11.850 Billion Infectious Diseases	6 **Dupixent** *Dupilumab* $11.565 Billion Immunology	7 **Stelara** *Ustekinumab* $11.297 Billion Immunology	8 **Comirnaty** *COVID-19 Vaccine, mRNA* $11.220 Billion Infectious Diseases	9 **Jardiance** *Empagliflozin* NIQBIB $10.600 Billion Diabetes	10 **Opdivo** *Nivolumab* $10.010 Billion Oncology	11 **Darzalex** *Daratumumab* $9.744 Billion Oncology	12 **Eylea** *Aflibercept* $9.225 Billion Ophthalmology	13 **Trikafta** *Elexacaftor, Tezacaftor & Ivacaftor* GEMMAQ, XIXBAK $8.944 Billion Genetic Diseases	14 **Gardasil** *HPV Quadrivalent Vaccine* $8.886 Billion Infectious Diseases	15 **Skyrizi** *Risankizumab* $7.763 Billion Immunology	16 **Ocrevus** *Ocrelizumab* $7.403 Billion Neurology	17 **Trulicity** *Dulaglutide* $7.132 Billion Diabetes	18 **Insulin** *Insulin* $6.979 Billion Diabetes	19 **Imbruvica** *Ibrutinib* BETXEG01 $6.860 Billion Oncology	20 **Xarelto** *Rivaroxaban* LEMSOO $6.793 Billion Cardiology/Vascular Diseases
21 **Prevnar Family** *Pneumococcal 7-Valent Conjugate* $6.440 Billion Infectious Diseases	22 **Revlimid** *Lenalidomide* AJISES $6.179 Billion Oncology	23 **Entresto** *Sacubitril & Valsartan* NAQLAU, KIPLIG $6.035 Billion Cardiology/Vascular Diseases	24 **Xtandi** *Enzalutamide* YEXGEQ $5.971 Billion Oncology	25 **Farxiga** *Dapagliflozin* CINSEZ $5.963 Billion Diabetes	26 **Tagrisso** *Osimertinib* $5.799 Billion Oncology	27 **Botox** *OnabotulinumtoxinA* $5.673 Billion Neurology	28 **Entyvio** *Vedolizumab* $5.280 Billion Immunology	29 **Mounjaro** *Tirzepatide* $5.163 Billion Diabetes	30 **Cosentyx** *Secukinumab* $4.980 Billion Immunology	31 **Hemlibra** *Emicizumab* $4.811 Billion Rare Diseases	32 **Ibrance** *Palbociclib* XOKJUG $4.753 Billion Oncology	33 **Enbrel** *Etanercept* $4.527 Billion Immunology	34 **Perjeta** *Pertuzumab* $4.371 Billion Oncology	35 **Tecentriq** *Atezolizumab* $4.369 Billion Oncology	36 **Imfinzi** *Durvalumab* $4.237 Billion Oncology	37 **Immunoglobulin** *Immunoglobulin* $4.210 Billion Immunology	38 **NovoRapid** *Insulin Aspart* $4.177 Billion Diabetes	39 **Invega Sustenna** *Paliperidone Palmitate* NOKFUR $4.115 Billion Neurology	40 **Prolia** *Denosumab* $4.048 Billion Musculoskeletal
41 **Lynparza** *Olaparib* JEPBUF $4.010 Billion Oncology	42 **Xolair** *Omalizumab* $3.987 Billion Immunology	43 **Rinvoq** *Upadacitinib* $3.969 Billion Immunology	44 **Verzenio** *Abemaciclib* $3.863 Billion Oncology	45 **Ofev** *Nintedanib* NAMPUQ $3.735 Billion Respiratory Diseases	46 **Shingrix** *Zoster Vaccine Recombinant, Adjuvanted* $3.719 Billion Infectious Diseases	47 **Orencia** *Abatacept* $3.601 Billion Immunology	48 **Pomalyst** *Pomalidomide* $3.441 Billion Oncology	49 **Vyndaqel** *Tafamidis* CEQDOV $3.321 Billion Rare Diseases	50 **Tremfya** *Guselkumab* $3.147 Billion Immunology	51 **Soliris** *Eculizumab* $3.145 Billion Hematology	52 **Actemra** *Tocilizumab* $3.051 Billion Immunology	53 **Vyvanse** *Lisdexamfetamine* $2.978 Billion Neurology	54 **Ultomiris** *Ravulizumab-cwvz* $2.965 Billion Hematology	55 **Lenvima** *Lenvatinib* HEFFEH $2.868 Billion Oncology	56 **Taltz** *Ixekizumab* $2.759 Billion Immunology	57 **Vraylar** *Cariprazine* UWUYOC $2.759 Billion Neurology	58 **Vabysmo** *Faricimab* $2.734 Billion Ophthalmology	59 **Rybelsus** *Semaglutide* $2.725 Billion Diabetes	60 **Calquence** *Acalabrutinib* $2.514 Billion Oncology
61 **Erleada** *Apalutamide* FAVYEK $2.387 Billion Oncology	62 **Trelegy Ellipta** *Fluticasone Furoate, Vilanterol Trifenatate & Umeclidinium* ABEFAR $2.376 Billion Respiratory Diseases	63 **Symbicort** *Budesonide & Formoterol* SHBUXP10, RUVWIO $2.362 Billion Respiratory Diseases	64 **Enhertu** *Trastuzumab Deruxtecan* $2.349 Billion Oncology	65 **Venclexta** *Venetoclax* AQUPEK $2.288 Billion Oncology	66 **Kadcyla** *Trastuzumab Emtansine* $2.280 Billion Oncology	67 **Promacta** *Eltrombopag* $2.269 Billion Oncology	68 **Cimzia** *Certolizumab Pegol* $2.253 Billion Immunology	69 **Yervoy** *Ipilimumab* $2.238 Billion Oncology	70 **Remicade** *Infliximab* $2.233 Billion Immunology	71 **Xgeva** *Denosumab* $2.212 Billion Oncology	72 **Simponi** *Golimumab* $2.197 Billion Immunology	73 **Januvia** *Sitagliptin* URAWUH $2.189 Billion Diabetes	74 **Otezla** *Apremilast* MAWSUB $2.188 Billion Dermatology	75 **Veklury** *Remdesivir* IQIMAZ $2.184 Billion Infectious Diseases	76 **Kesimpta** *Ofatumumab* $2.171 Billion Neurology	77 **Kisqali** *Ribociclib* VEWFIQ $2.080 Billion Oncology	78 **Rexulti** *Brexpiprazole* PEWNIR $2.069 Billion Neurology	79 **Genvoya** *Elvitegravir, Cobicistat & Tenofovir Alafenamide* BUKQOQ $2.060 Billion Infectious Diseases	80 **Lucentis** *Ranibizumab* $2.008 Billion Ophthalmology
81 **Descovy** *Emtricitabine & Tenofovir Alafenamide* HAKJIM, BUKQOQ $1.985 Billion Infectious Diseases	82 **Opsumit** *Macitentan* VEMRAI $1.973 Billion Cardiology/Vascular Diseases	83 **Dovato** *Dolutegravir & Lamivudine* KILNEA, RUKHAG $1.963 Billion Infectious Diseases	84 **Sprycel** *Dasatinib* RAVPUB $1.930 Billion Oncology	85 **Tafinlar** *Dabrafenib & Trametinib* GICKEM, KELFOA $1.922 Billion Oncology	86 **MabThera** *Rituximab* $1.891 Billion Oncology	87 **Herceptin** *Trastuzumab* $1.886 Billion Oncology	88 **Tysabri** *Natalizumab* $1.876 Billion Neurology	89 **Prezista** *Darunavir & Cobicistat* NISTIV $1.854 Billion Infectious Diseases	90 **Tasigna** *Nilotinib* URAVUG $1.848 Billion Oncology	91 **Bridion** *Sugammadex* OGIZEJ $1.842 Billion Neurology	92 **Ingrezza** *Valbenazine* $1.836 Billion Neurology	93 **Avastin** *Bevacizumab* $1.825 Billion Oncology	94 **Trajenta** *Linagliptin & Metformin* XEJMAD, PAJBUY $1.815 Billion Diabetes	95 **Gilenya** *Fingolimod* HUCHEU $1.811 Billion Neurology	96 **Nucala** *Mepolizumab* $1.786 Billion Immunology	97 **Alecensa** *Alectinib* COVTAM $1.742 Billion Oncology	98 **Spinraza** *Nusinersen* $1.741 Billion Genetic Diseases	99 **Jakavi** *Ruxolitinib* $1.720 Billion Oncology	100 **Lixiana** *Edoxaban* $1.706 Billion Hematology
101 **Xeljanz** *Tofacitinib* $1.703 Billion Immunology	102 **Zyprexa** *Olanzapine* UNOGIN $1.694 Billion Neurology	103 **Triumeq** *Abacavir, Dolutegravir & Lamivudine* MUBPAB, KILNEA, RUKHAG $1.664 Billion Infectious Diseases	104 **Humalog** *Insulin Lispro* $1.663 Billion Diabetes	105 **Evrysdi** *Risdiplam* $1.646 Billion Neurology	106 **Repatha** *Evolocumab* $1.635 Billion Cardiology/Vascular Diseases	107 **Uptravi** *Selexipag* VOHVIA $1.582 Billion Cardiology/Vascular Diseases	108 **Creon** *Pancrelipase* $1.572 Billion Rare Diseases	109 **Lipitor** *Atorvastatin* IZOQIZ $1.559 Billion Cardiology/Vascular Diseases	110 **Fasenra** *Benralizumab* $1.553 Billion Respiratory Diseases	111 **Epclusa** *Sofosbuvir & Velpatasvir* CUZROG02 $1.537 Billion Infectious Diseases	112 **Lantus** *Insulin Glargine* $1.532 Billion Diabetes	113 **Yescarta** *Axicabtagene Ciloleucel* $1.498 Billion Oncology	114 **Tivicay** *Dolutegravir* KILNEA $1.495 Billion Infectious Diseases	115 **Saxenda** *Liraglutide* $1.495 Billion Nutritional Deficiency	116 **Kyprolis** *Carfilzomib* $1.478 Billion Oncology	117 **Nplate** *Romiplostim* $1.477 Billion Immunology	118 **Benlysta** *Belimumab* $1.456 Billion Immunology	119 **Mavyret** *Glecaprevir & Pibrentasvir* $1.430 Billion Infectious Diseases	120 **Lagevrio** *Molnupiravir* DOSBOG $1.428 Billion Infectious Diseases
121 **Brukinsa** *Zanubrutinib* FOWQIU $1.396 Billion Oncology	122 **Juvederm** *Hyaluronic Acid* $1.378 Billion Dermatology	123 **Spiriva** *Tiotropium* GUYGOX03 $1.372 Billion Respiratory Diseases	124 **Prograf** *Tacrolimus* FINWEE $1.365 Billion Immunology	125 **Aranesp** *Darbepoetin Alfa* $1.362 Billion Hematology	126 **Activase** *Alteplase & Tenecteplase* $1.360 Billion Cardiology/Vascular Diseases	127 **Ilaris** *Canakinumab* $1.355 Billion Immunology	128 **Abilify Maintena** *Aripiprazole* MELFIT01 $1.350 Billion Neurology	129 **Odefsey** *Emtricitabine, Rilpivirine & Tenofovir Alafenamide* HAKJIM, OMAKOE01, BUKQOQ $1.350 Billion Infectious Diseases	130 **Adempas** *Riociguat* HECPAJ $1.338 Billion Cardiology/Vascular Diseases	131 **Brilinta** *Ticagrelor* JEMWIK $1.324 Billion Cardiology/Vascular Diseases	132 **Sandostatin** *Octreotide* YICMUS $1.314 Billion Oncology	133 **Mirena** *Levonorgestrel* NORGES01 $1.311 Billion Women's Health	134 **Phesgo** *Pertuzumab, Trastuzumab & Hyaluronidase* $1.299 Billion Oncology	135 **Betanis** *Mirabegron* HOCHAM $1.283 Billion Nephrology	136 **Nexgard** *Afoxolaner* $1.282 Billion Infectious Diseases	137 **Paxlovid** *Ritonavir & Nirmatrelvir* YIGPIO01, ZIVMEA $1.279 Billion Infectious Diseases	138 **Xywav** *Ca, Mg, K and Na Oxybates* $1.272 Billion Sleep	139 **Victoza** *Liraglutide* $1.259 Billion Diabetes	140 **Seretide** *Salmeterol* URAWER $1.229 Billion Respiratory Diseases
141 **Austedo** *Deutetrabenazine* $1.225 Billion Neurology	142 **Evenity** *Romosozumab-aqqg* $1.224 Billion Musculoskeletal	143 **Jynarque** *Tolvaptan* NOKGAY $1.223 Billion Cardiology/Vascular Diseases	144 **Reblozyl** *Luspatercept-aamt* $1.220 Billion Hematology	145 **Abraxane** *Paclitaxel Protein Bound* RIGKUP $1.216 Billion Oncology	146 **Lovenox** *Enoxaparin* $1.214 Billion Hematology	147 **Zolgensma** *Onasemnogene Abeparvovec-xioi* $1.214 Billion Neurology	148 **Toujeo** *Insulin Glargine* $1.212 Billion Diabetes	149 **Relvar** *Fluticasone Furoate* $1.190 Billion Respiratory Diseases	150 **Janumet** *Sitagliptin & Metformin* URAWUH, PAJBUY $1.177 Billion Diabetes	151 **Takhzyro** *Lanedelumab-flyo* $1.168 Billion Genetic Diseases	152 **Vectibix** *Panitumumab* $1.162 Billion Oncology	153 **Strensiq** *Asfotase Alfa* $1.152 Billion Metabolic Diseases	154 **Somatuline** *Lanreotide* $1.150 Billion Oncology	155 **Edurant** *Rilpivirine* OMAKOE01 $1.150 Billion Infectious Diseases	156 **Tresiba** *Insulin Degludec* $1.126 Billion Diabetes	157 **Covid-19 Vaccine** *Ad26.COV2-S [recombinant]* $1.117 Billion Infectious Diseases	158 **Crestor** *Rosuvastatin* ZIPDEJ $1.113 Billion Cardiology/Vascular Diseases	159 **Linzess** *Linaclotide* $1.108 Billion Gastrointestinal Diseases	160 **Crysvita** *Burosumab-twza* $1.103 Billion Genetic Diseases
161 **Fabrazyme** *Agalsidase Beta* $1.069 Billion Rare Diseases	162 **Trodelvy** *Sacituzumab Govitecan* $1.063 Billion Oncology	163 **Iniyta** *Axitinib* VUSDIX $1.036 Billion Oncology	164 **Aubagio** *Teriflunomide* DOSCUM $1.030 Billion Neurology	165 **Plavix** *Clopidogrel* FUQMOU $1.023 Billion Cardiology/Vascular Diseases	166 **Tecfidera** *Dimethyl Fumarate* ZZZDRQ01 $1.012 Billion Neurology	167 **Simponi** *Golimumab* $1.002 Billion Immunology	168 **Pluvicto** *Lutetium-177 Vipivotide Tetraxetan* $980 Million Oncology	169 **Cyramza** *Ramucirumab* $974 Million Oncology	170 **Polivy** *Polatuzumab Vedotin-piiq* $971 Million Oncology	171 **Zoladex** *Goserelin* $952 Million Oncology	172 **Nexium** *Esomeprazole* FOPYOZ $945 Million Gastrointestinal Diseases	173 **Nubeqa** *Darolutamide* $942 Million Oncology	174 **Gazyva** *Obinutuzumab* $940 Million Oncology	175 **Nurtec ODT** *Rimegepant* XIVSAY $928 Million Neurology	176 **Olumiant** *Baricitinib* NEBZIH $922 Million Immunology	177 **Blincyto** *Blinatumomab* $919 Million Oncology	178 **Bexsero** *Meningococcal Vaccine* $916 Million Infectious Diseases	179 **Pradaxa** *Dabigatran Etexilate* EFAXAM $899 Million Hematology	180 **Albumin** *Albumin* $887 Million Immunology
181 **Zytiga** *Abiraterone Acetate* QOVCEL01 $887 Million Oncology	182 **Libtayo** *Cemiplimab-rwlc* $863 Million Oncology	183 **Vemlidy** *Tenofovir Disoproxil* TEDTUU $862 Million Infectious Diseases	184 **Humulin** *Insulin Isophane* $852 Million Diabetes	185 **Epidiolex** *Cannabidiol* CANDOM16 $845 Million Neurology	186 **Myozyme** *Agalsidase Alfa* $845 Million Rare Diseases	187 **Nexplanon** *Etonogestrel* FUGSEF $830 Million Women's Health	188 **Advate** *Antihemophilic Factor (Recombinant)* $818 Million Rare Diseases	189 **Ubrelvy** *Ubrogepant* $815 Million Neurology	190 **Avonex** *Interferon Beta-1a* $811 Million Neurology	191 **Ventolin** *Albuterol* BHHPHE $808 Million Respiratory Diseases	192 **Kogenate** *Antihemophilic Factor (Recombinant)* $800 Million Rare Diseases	193 **Alprolix** *Coagulation Factor IX (Recombinant), Fc Fusion Protein* $786 Million Rare Diseases	194 **Concerta** *Methylphenidate* CAJJEF $783 Million Neurology	195 **Takecab** *Vonoprazan* UCIROR $780 Million Gastrointestinal Diseases	196 **Synagis** *Palivizumab* $778 Million Immunology	197 **Cabenuva** *Cabotegravir & Rilpivirine* OMAKOE01 $764 Million Infectious Diseases	198 **Sulperazon** *Cefoperazone & Sulbactam* BAFVOT $757 Million Infectious Diseases	199 **Adcetris** *Brentuximab Vedotin* $744 Million Oncology	200 **Cerezyme** *Imiglucerase* $741 Million Rare Diseases

Adapted from the poster compiled and produced by the Njardarson group (The University of Arizona), J. Chem. Ed. 2010, 87, 1348

Key: Green = Crystal structure in the CSD; Grey = Biological structure in the PDB; White = CSD crystal structure pending

Poster design by Phil Andrews, CCDC, 2021 - 2024

CCDC
advancing structural science